• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

STAT3-siRNA induced B16.F10 melanoma cell death: Association with VEGF downregulation than p-STAT3 knockdown
Publication date: Available online 30 May 2018 Source:Saudi Pharmaceutical Journal Author(s): Aws Alshamsan STAT3 knockdown by small interfering RNA (siRNA) has been described to inhibit carcinogenic growth in various types of tumors. Earlier we have reported delivery of siRNA by oleic acid- and stearic acid-modified-polyethylenimine and enhancement of silencing of STAT3 by small interfering RNA (siRNA) in B16.F10 melanoma cell lines and consequent tumor suppression. Present investigation mainly focused on the downstream events involved in B16.F10 melanoma cell death and consequent tumor suppression following knockdown of...
Source: Saudi Pharmaceutical Journal - May 31, 2018 Category: Drugs & Pharmacology Source Type: research

STAT3-siRNA induced B16.F10 melanoma cell death: more association with VEGF downregulation than p-STAT3 knockdown
Publication date: Available online 30 May 2018 Source:Saudi Pharmaceutical Journal Author(s): Aws Alshamsan STAT3 knockdown by small interfering RNA (siRNA) has been described to inhibit carcinogenic growth in various types of tumors. Earlier we have reported delivery of siRNA by oleic acid- and stearic acid-modified-polyethylenimine and enhancement of silencing of STAT3 by small interfering RNA (siRNA) in B16.F10 melanoma cell lines and consequent tumor suppression. Present investigation mainly focused on the downstream events involved in B16.F10 melanoma cell death and consequent tumor suppression following knockdown of...
Source: Saudi Pharmaceutical Journal - June 6, 2018 Category: Drugs & Pharmacology Source Type: research

Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
Abstract The aim of the present study was to evaluate the effectiveness of iontophoretic co-delivery of curcumin and anti-STAT3 siRNA using cationic liposomes against skin cancer. Curcumin was encapsulated in DOTAP-based cationic liposomes and then complexed with STAT3 siRNA. This nanocomplex was characterized for the average particle size, zeta-potential, and encapsulation efficiency. The cell viability studies in B16F10 mouse melanoma cells have shown that the co-delivery of curcumin and STAT3 siRNA significantly (p < 0.05) inhibited the cancer cell growth compared with either liposomal curcumin or STAT3 si...
Source: AAPS PharmSciTech - June 21, 2017 Category: Drugs & Pharmacology Authors: Jose A, Labala S, Ninave KM, Gade SK, Venuganti VVK Tags: AAPS PharmSciTech Source Type: research

Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma
SummaryThe use of small interfering RNA (siRNA) in melanoma treatment remains limited owing to its biological properties. Herein, we developed a carrier system containing hyaluronic acid and protamine for siRNA delivery. Considering zeta potential and particle size as standards, the ratio of each component in liposome nanoparticles prepared was screened using the control variable method, and siRNA cationic liposome nanoparticles were prepared based on the optimal results obtained. The encapsulation rate of the cationic liposome nanoparticles was measured, and particle morphology was observed. B16F10 cells were treated with...
Source: Investigational New Drugs - August 12, 2020 Category: Drugs & Pharmacology Source Type: research

Current non-viral siRNA delivery systems as a promissing treatment of skin diseases.
CONCLUSION: The treatment of skin diseases based on topical delivery of siRNA, which act by inhibiting the expression of target transcripts, offers many potential therapeutic advantages for suppressing genes into the skin. PMID: 30084329 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Rosa J, Suzuki I, Kravicz M, Caron A, Pupo AV, Praca FG, Bentley MVLB Tags: Curr Pharm Des Source Type: research

Inhibition of Cancer Cell Growth by GRP78 siRNA Lipoplex via Activation of Unfolded Protein Response.
Abstract Proteasome inhibitors are a novel class of molecular-targeted anti-cancer drugs that suppress the degradation of malfolded proteins, trigger endoplasmic reticulum (ER) stress, and activate apoptosis signals. Glucose-regulated protein 78 (GRP78), a major ER chaperone, is one of the most important molecules for transduction of unfolded protein response (UPR) signals. In accordance with past findings that expression of GRP78 is elevated in cancer cells and helps to resist stress-induced apoptosis, GRP78 knockdown could be effective in anticancer therapy. We tested this hypothesis and found that transfection ...
Source: Biological and Pharmaceutical Bulletin - April 6, 2014 Category: Drugs & Pharmacology Authors: Matsumura K, Sakai C, Kawakami S, Yamashita F, Hashida M Tags: Biol Pharm Bull Source Type: research

Efficient Inhibition of Uveal Melanoma via Ternary siRNA Complexes
Publication date: Available online 23 November 2019Source: International Journal of PharmaceuticsAuthor(s): Lingxiao Xie, Yan Yang, Jie ShenAbstractUveal melanoma (UM) is rare yet the most common and malignant primary intraocular tumor in adults. Due to the lack of effective treatment, the mortality rate of UM has remained high over the past few decades. In the present study, hyaluronic acid (HA) coated chitosan (Chi)/siRNA ternary complexes have been developed and characterized as a novel therapeutic strategy molecularly targeting hypoxia-inducible factor 1α (HIF-1α) pathway for the treatment of UM. The cytotoxicity, ce...
Source: International Journal of Pharmaceutics - November 23, 2019 Category: Drugs & Pharmacology Source Type: research

Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA.
In conclusion, PBA-modified COSs can serve as a promising carrier for siRNA delivery in the field of anti-tumor therapy. PMID: 33220463 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - November 18, 2020 Category: Drugs & Pharmacology Authors: Liu X, Chen L, Zhang Y, Xin X, Qi L, Jin M, Guan Y, Gao Z, Huang W Tags: Eur J Pharm Sci Source Type: research

Coated microneedles mediated intradermal delivery of octaarginine/BRAF siRNA nanocomplexes for anti-melanoma treatment
In this study, we for the first time developed a siBraf delivery system based on cell penetrating peptide octaarginine (R8) nanocomplexes combined with coated microneedles (MNs), i.e. R8/siBraf coated MNs, for targeted anti–melanoma treatment. The R8/siBraf nanocomplexes were optimized based on the internalization of siBraf by A375 cells. In vitro A375 cell experiments presented that R8/siBraf can enhance siBraf transfection, silence BRAF gene, and inhibit tumor cells growth, comparable to polyethylenimine (PEI)/siBraf. R8/siBraf coated MNs can effectively deliver R8/siBraf into the disease site. In vivo anti-melanoma ex...
Source: International Journal of Pharmaceutics - October 20, 2018 Category: Drugs & Pharmacology Source Type: research

Cyclin B1 knockdown mediated by clinically approved pulsed electric fields siRNA delivery induces tumor regression in murine melanoma
Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Aurélie Paganin-Gioanni, Marie-Pierre Rols, Justin Teissié, Muriel GolzioAbstractRNA interference (RNAi) represents a promising therapy for the specific inhibition of gene expression in targeted tissues including tumors. To realize the therapeutic potential of RNAi drugs, non-immunogenic, efficient, and tissue-specific delivery technologies must be developed. We have previously shown that pulsed electric field (PEF) can deliver siRNAs into tumor cells thanks to long electrophoretic drift occurring during the use of ...
Source: International Journal of Pharmaceutics - November 9, 2019 Category: Drugs & Pharmacology Source Type: research

Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle
ConclusionOverall, results revealed that the tumors treated with siPDIN restored the immunity of CTLs by potentially inhibiting the immune checkpoint interactions, suppressed the mTOR signaling pathway and exhibited an enhanced anticancer efficacy in melanoma.
Source: Pharmaceutical Research - May 30, 2020 Category: Drugs & Pharmacology Source Type: research

Nanocarriers for Sirna Delivery Aimed at the Treatment of Melanoma: Systematic Review
CONCLUSION: Such being the case, the development of these systems becomes a non-invasive and promising option for the treatment of melanoma.PMID:37170995 | DOI:10.2174/1567201820666230425234700
Source: Current Drug Delivery - May 12, 2023 Category: Drugs & Pharmacology Authors: Brenda Regina de Araujo Tatielle do Nascimento Ana Paula Dos Santos Matos Vanessa Brand ão de Souza Belmiro Mariana Sato de Souza de Bustamante Monteiro Ralph Santos-Oliveira Eduardo Ricci-Junior Source Type: research

Pages: 1  2  3  4  5  6